132 related articles for article (PubMed ID: 38596295)
1. Immune checkpoint inhibitors: breakthroughs in cancer treatment.
Kong X; Zhang J; Chen S; Wang X; Xi Q; Shen H; Zhang R
Cancer Biol Med; 2024 May; ():. PubMed ID: 38801082
[TBL] [Abstract][Full Text] [Related]
2. The role of immunotherapy in urological cancers.
Bosnali E; Akdas EM; Telli E; Teke K; Kara O
Arch Ital Urol Androl; 2024 May; ():12307. PubMed ID: 38818794
[TBL] [Abstract][Full Text] [Related]
3. The transcriptomic expression pattern of immune checkpoints shows heterogeneity between and within cancer types.
Miyashita H; Bevins NJ; Thangathurai K; Lee S; Pabla S; Nesline MK; Glenn ST; Conroy JM; DePietro P; Rubin E; Sicklick JK; Kato S; Kurzrock R
Am J Cancer Res; 2024; 14(5):2240-2252. PubMed ID: 38859855
[TBL] [Abstract][Full Text] [Related]
4. Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party.
Lu C; Tan Y
Mol Ther Oncol; 2024 Mar; 32(1):200773. PubMed ID: 38596295
[TBL] [Abstract][Full Text] [Related]
5. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
Kok VC
Front Oncol; 2020; 10():268. PubMed ID: 32185135
[TBL] [Abstract][Full Text] [Related]
6. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
7. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.
Vaddepally RK; Kharel P; Pandey R; Garje R; Chandra AB
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245016
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
9. [Progress on tumor immune checkpoints and their inhibitors in tumor therapy].
Wang L; Bai L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jul; 37(7):663-670. PubMed ID: 34140079
[TBL] [Abstract][Full Text] [Related]
10. LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy.
Ibrahim R; Saleh K; Chahine C; Khoury R; Khalife N; Cesne AL
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509517
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.
Phillips AL; Reeves DJ
Ann Pharmacother; 2023 Jun; 57(6):738-745. PubMed ID: 36268952
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer.
Shi AP; Tang XY; Xiong YL; Zheng KF; Liu YJ; Shi XG; Lv Y; Jiang T; Ma N; Zhao JB
Front Immunol; 2021; 12():785091. PubMed ID: 35111155
[TBL] [Abstract][Full Text] [Related]
13. A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Mettu NB; Ulahannan SV; Bendell JC; Garrido-Laguna I; Strickler JH; Moore KN; Stagg R; Kapoun AM; Faoro L; Sharma S
Clin Cancer Res; 2022 Mar; 28(5):882-892. PubMed ID: 34844977
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]